Compare D961H 20 mg Bid and 20 mg qd in Patients With Refractory Reflux Esophagitis (Inflammation of Lower Esophagus)
Status:
Completed
Trial end date:
2014-05-01
Target enrollment:
Participant gender:
Summary
This is a phase 3 multicentre, randomised, double-blind, parallel-group, comparative study to
evaluate the efficacy of esomeprazole (D961H) 20 mg twice daily and esomeprazole (D961H) 20
mg once daily in patients (in the form of esomeprazole magnesium salt) with refractory reflux
esophagitis after 8 weeks of standard Proton-pump inhibitor (PPI) therapy by assessment of
presence/absence of inflammation (esophagitis) at Week 8 according to the Los Angeles (LA)
classification